Revolution Medicines GAAP EPS of -$0.87 misses by $0.02, revenue of $3.4M misses by $2.94M

Nov. 07, 2022 4:22 PM ETRevolution Medicines, Inc. (RVMD)By: Urvi Shah, SA News Editor
  • Revolution Medicines press release (NASDAQ:RVMD): Q3 GAAP EPS of -$0.87 misses by $0.02.
  • Revenue of $3.4M (+209.1% Y/Y) misses by $2.94M.
  •  Cash, cash equivalents and marketable securities were $655.0 million as of September 30, 2022, compared to $577.1 million as of December 31, 2021. 
  •  Net loss was $73.3 million for the quarter ended September 30, 2022, compared to net loss of $52.9 million for the quarter ended September 30, 2021.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.